Radiotherapy-induced Nausea and Vomiting

Kristopher Dennis; Ernesto Maranzano; Carlo De Angelis; Lori Holden; Shun Wong; Edward Chow


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(6):685-692. 

In This Article

General Guideline Issues

When chemotherapy is administered concurrently with radiotherapy, in general each of the three guidelines suggests that practitioners use the recommended antiemetic strategies for the chemotherapy agents being used rather than those for the radiotherapy being delivered.

A final note is that these guidelines do not formally integrate patient-related risk factors into their recommendations, although suggestions to do so have been made for many years.[14] The MASCC/ESMO guidelines have proposed risk-adjusted antiemetic models that use scoring systems to allow an individual patient's projected risk of RINV to be modified by their status with respect to the following risk factors: age, gender, alcohol consumption, previous nausea/vomiting and anxiety.[2,9] Unfortunately this logical approach cannot be followed at present as more observational data are required to confirm the validity and reliability of these risk factors.